pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›EYLEA HD
drug · protein
save

EYLEA HD

Marketedupdated 6mo ago
by $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
Approved
annual revenue · 2024–2024peak $9.4B
2024: $9.4B2024$9.4B
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval44 co-mentions · 15 sources
  • drugEylea32 co-mentions · 15 sources
  • drugYESAFILI18 co-mentions · 7 sources
  • drugaflibercept biosimilar17 co-mentions · 10 sources
  • drugOPUVIZ8 co-mentions · 4 sources
  • drugENZEEVU6 co-mentions · 3 sources
  • companySamsung Bioepis Co Ltd4 co-mentions · 4 sources
  • companyBiocon Biologics Ltd4 co-mentions · 2 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with 16 approved and 39 investigational indications.

indications

investigational
Diabetic Macular Edema

targets

Placenta growth factorVascular endothelial growth factor A, long form

all catalysts(5)

approval · 5
Aug 18, 2023
approval
$REGN920.69-0.19%
3y ago
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Dec 14, 2023
approval
$REGN920.69-0.19%
3y ago
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Oct 10, 2024
approval
$REGN920.69-0.19%
2y ago
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Nov 19, 2025
approval
$REGN920.69-0.19%
1y ago
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→
Apr 2, 2026
approval
$REGN920.69-0.19%
8mo ago
EYLEA HD (AFLIBERCEPT) — FDA approval
EYLEA HD
→

Trials studying EYLEA HD

  • phase3A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Macular Edema After Retinal Vein Occlusion (MK-8748-006)not yet recruitingn=1,188
  • phase3A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).recruitingn=514
  • phase2RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)completedn=139
  • phase3A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56active not recruitingn=400
  • phase2A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degenerationnot yet recruitingn=244
  • —An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)recruitingn=200
  • phase3CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEactive not recruitingn=240
  • phase3Aflibercept After Ranibizumab in Exudative Age-related Macular Degenerationcompletedn=84

News(10)

  • With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
    The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
    biopharma_dive · 2d ago
  • J&J bets $2.2B on Ollin’s vision loss drug
    The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
    biopharma_dive · 5d ago
  • J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
    Johnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.
    fiercebiotech · 5d ago
  • Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
    AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.
    biopharma_dive · 19d ago
  • Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
    Regeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s…
    biospace · 22d ago
  • EyePoint will halve workforce, end pivotal wet AMD trials early following second fail
    EyePoint is initiating a strategic review after duravyu failed another Phase 3 trial in wet age-related macular degeneration. Amid significant layoffs and trial terminations, the company is shiftin…
    biospace · 1mo ago
  • This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
    The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.
    biopharma_dive · 1mo ago
  • Lilly, Foghorn part ways; Wave’s FDA-approved plans
    The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
    biopharma_dive · 1mo ago
  • Kodiak skyrockets on positive study data for 2 eye drugs
    The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
    biopharma_dive · 1mo ago
  • Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor
    Kodiak Sciences appears to have an Eylea successor on its hands. The Silicon Valley biotech said its experimental drug Zenkuda performed as well as Eylea in a progressive eye disease known as wet a…
    endpoints · 1mo ago
view all news mentions →
brand
EYLEA HD
trade names
Eylea, Yesafili, Zaltrap
generic
AFLIBERCEPT
MOA
12.1 Mechanism of Action Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of leucocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, and thereby can inhibit the binding and activation of these cognate VEGF receptors.
indication
wet AMD, diabetic macular edema, retinal vein occlusion
phase
marketed
approved
2011-11-18
Data sources
openFDA · ClinicalTrials.gov · OpenTargets
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?